Curium, a leading nuclear medicine company, has submitted a New Drug Application to the FDA for Lutetium Lu 177 Dotatate Injection. This drug would be used for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). The submission is a significant step in Curium's strategy to become a major player in the nuclear medicine therapeutic field. Curium has developed its formulation over several years and made sure it did not infringe on any Orange Book listed patents to fast-track its path to market. The company is looking forward to working closely with the FDA through the review and approval process, with the aim of providing more patients with access to the potential benefits of radioligand therapy.
Tue, 09 Jul 2024 13:48:54 GMT | GlobeNewswire